(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
Public ClinicalTrials.gov record NCT02047604. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients with Active Rheumatoid Arthritis with Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Study identification
- NCT ID
- NCT02047604
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 41 participants
Conditions and interventions
Conditions
Interventions
- SAN-300 0.5 mg/kg QW Drug
- SAN-300 1.0 mg/kg QW Drug
- SAN-300 2.0 mg/kg QOW Drug
- SAN-300 4.0 mg/kg QOW Drug
- SAN-300 4.0 mg/kg QW Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2013
- Primary completion
- Feb 22, 2017
- Completion
- Mar 22, 2017
- Last update posted
- Jun 20, 2021
2013 – 2017
United States locations
- U.S. sites
- 12
- U.S. states
- 7
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Santarus Clinical Investigational Site 1012 | Phoenix | Arizona | 85023 | — |
| Santarus Clinical Investigational Site 1004 | El Cajon | California | 92020 | — |
| Santarus Clinical Investigational Site 1008 | Los Angeles | California | 90048 | — |
| Santarus Clinical Investigational Site 1011 | San Leandro | California | 94578 | — |
| Santarus Clinical Investigational Site 1013 | Brandon | Florida | 33511 | — |
| Santarus Clinical Investigational Site 1003 | Palm Harbor | Florida | 34684 | — |
| Santarus Clinical Investigational Site 1017 | Florissant | Missouri | 63031 | — |
| Santarus Clinical Investigational Site 1009 | Brooklyn | New York | 11201 | — |
| Santarus Clinical Investigational Site 1019 | Chapel Hill | North Carolina | 27599 | — |
| Santarus Clinical Investigational Site 1014 | Charlotte | North Carolina | 28210 | — |
| Santarus Clinical Investigational Site 1006 | Salisbury | North Carolina | 28144 | — |
| Santarus Clinical Investigational Site 1001 | Middleburg Heights | Ohio | 44130 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Rheumatoid Arthritis trials
Other public records listing Rheumatoid Arthritis. Sorted by last update posted; newest first. Not a recommendation.
- NCT07137598: A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) Recruiting
- NCT04817969: Persona Ti-Nidium Post-Market Clinical Follow-up Active, not recruiting
- NCT07620392: An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis Recruiting
- NCT05936970: Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to a DMARD Starting a New bDMARD or tsDMARD Treatment +/- csDMARD Active, not recruiting
- NCT07704580: Phase 1b/2 Study of IV Sarilumab in Adult With RA Recruiting
- NCT07293871: Ultrasound Neuroimmune Modulation in Adults With Rheumatoid Arthritis Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02047604, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 20, 2021 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02047604 live on ClinicalTrials.gov.